Back to results

CompletedPhase 1Phase 2

Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease

NCT00985517

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

University of Alabama at Birmingham

Birmingham, Alabama, United States

+10 additional locations

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2009-10-29
Enrollment: 57 participants
Sponsor: Sangamo Therapeutics
Purpose: treatment

Locations (11)

University of Alabama at BirminghamBirmingham, Alabama, United States
Stanford School of MedicinePalo Alto, California, United States
University of California, San FranciscoSan Francisco, California, United States
Emory UniversityAtlanta, Georgia, United States
Rush University Medical CenterChicago, Illinois, United States
Beth Israel Medical CenterNew York, New York, United States
Columbia University Medical CenterNew York, New York, United States
Mount Sinai Medical CenterNew York, New York, United States
Duke UniversityDurham, North Carolina, United States
University of PennsylvaniaPhiladelphia, Pennsylvania, United States
Baylor College of MedicineHouston, Texas, United States

Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease — TrialFind